AI CuratorAI-generated

Research summary · 4 h ago

AI summary · not yet reviewedSubjects not reportedNot reportedPublished in a peer-reviewed journal

Pediatric-Onset Multiple Sclerosis (POMS) in Gulf Countries: Data from Kuwait, Saudi Arabia, and UAE

Data on pediatric-onset MS (POMS) were gathered from Kuwait, Saudi Arabia, and the UAE, showing incidence rates ranging from 2.1 to 7.2 per 100,000. The UAE reported the highest prevalence (2.7-36 per 100,000). Relapsing-remitting courses were noted, with a higher occurrence in females and common presentations including brainstem/cerebellar symptoms and visual issues.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42940001)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not established from this source
Mechanism: Not reported
Evidence strength: Not graded
Outcome: Not reported

Why it matters

These findings provide insight into the epidemiology of pediatric-onset MS in the Gulf region, highlighting the need for targeted research in this area.

What this does not prove

The evidence is narrow, heterogeneous, and lacks substantial MRI, cognitive, and quality-of-life data; a comprehensive scoping review is needed for better insights.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: Not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-09-28
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified
Biological target: Not reported
Pathway: Not reported
Population: Pediatric-onset MS (onset before age 18)
Size of effect: Not reported
Secondary endpoints: Not reported
MRI endpoints: Not reported
Biomarkers: Not reported
Safety: Not reported

Original sources

Primary evidencePediatric-Onset Multiple Sclerosis in the Gulf: A Scoping Review of the Current Evidence Base and Research Gaps. ↗DOI: 10.3390/biomedicines14102195

Supporting passages (5)

publication date2026-09-28

findingsDedicated, pediatric-specific POMS data were identified from three of six countries: Kuwait (three epidemiological/clinical registry studies and two pediatric monoclonal-antibody outcome studies), Saudi Arabia (one national-registry study), and the UAE (two hospital/multicenter cohorts and one pediatric monoclonal-antibody outcome study).

limitationsConclusion: The Gulf POMS evidence base is real but narrow, concentrated, and heterogeneous; a scoping review, which maps the evidence base and treats geographic and domain gaps as findings in their own right, is currently the more informative synthesis than a quantitative meta-analysis.

populationBackground: MS begins before age 18 in 3-10% of cases (pediatric-onset MS, POMS).

peer reviewedPublication types: Journal Article; Review

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.